Photo: Depositphotos
May 30, 2025, 14:17
CureMatch Highlights Patient Recruitment Challenges in Clinical Trials Ahead of ASCO Annual Meeting 2025
CureMatch shared a post on X:
“Clinical trials take ten years and cost $2 billion on average, with the patient recruitment bottleneck representing roughly 35% of that. More optimal tools for patient stratification and matching can accelerate this process and help get the treatments to patients faster.”
Earlier this week CureMatch shared on X:
“Our ASCO25 paper Scoring approach 1st of kind predicting clinical trial outcomes using NGS +drug targeting profile, found patients who didn’t have prominent markers, YET did fairly well. For treatment planning and to qualify/quantify known+ novel drugs.
Thank you to our incredible team, our founder Razelle Kurzrock, Syneos Health and Dr. Harb, TransThera Sciences, ASCO.”
Abstract Title: Use of an in-silico clinical trial intelligence solution to predict outcomes of tinengotinib, a potent multi-kinase small molecule FGFR inhibitor in patients with cholangiocarcinoma, based on the molecular matching score.
Authors: Ally Perlina, Milind Javle, Subha Krishnan, Katie Hennessy, Hui Wang, Caixia Sun, Peng Peng, Navid Alipour, Wael Harb, Jean Fan, Razelle Kurzrock
Read Full Abstract at ASCO.
More posts featuring ASCO 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 30, 2025, 13:19
May 30, 2025, 12:53
May 30, 2025, 12:46
May 30, 2025, 12:32